312 related articles for article (PubMed ID: 37763107)
21. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
24. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
25. The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies.
Nicolaou KC; Rigol S
Angew Chem Int Ed Engl; 2019 Aug; 58(33):11206-11241. PubMed ID: 31012193
[TBL] [Abstract][Full Text] [Related]
26. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.
Martin C; Kizlik-Masson C; Pèlegrin A; Watier H; Viaud-Massuard MC; Joubert N
MAbs; 2018; 10(2):210-221. PubMed ID: 29239690
[TBL] [Abstract][Full Text] [Related]
27. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
28. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
29. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Drug Conjugates as a Targeted Therapeutic Approach Across Entities in Oncology.
Lordick F; Merz M; Büch E; Aigner A
Dtsch Arztebl Int; 2023 May; 120(19):329-336. PubMed ID: 37073718
[TBL] [Abstract][Full Text] [Related]
31. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
Ceci C; Lacal PM; Graziani G
Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
[TBL] [Abstract][Full Text] [Related]
32. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
33. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
Parakh S; Nicolazzo J; Scott AM; Gan HK
Front Oncol; 2021; 11():718590. PubMed ID: 34926242
[TBL] [Abstract][Full Text] [Related]
34. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
[TBL] [Abstract][Full Text] [Related]
36. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates: A Comprehensive Review.
Khongorzul P; Ling CJ; Khan FU; Ihsan AU; Zhang J
Mol Cancer Res; 2020 Jan; 18(1):3-19. PubMed ID: 31659006
[TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody-drug conjugate development.
Ma Q; Durga P; Wang FXC; Yao HP; Wang MH
Drug Discov Today; 2024 Jun; 29(8):104057. PubMed ID: 38844064
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Drug Conjugates for Cancer Treatment.
Lambert JM; Berkenblit A
Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
[TBL] [Abstract][Full Text] [Related]
40. [Antibody-drug conjugates in oncology. New strategies in development].
Beck A; Dumontet C; Joubert N
Med Sci (Paris); 2019 Dec; 35(12):1043-1053. PubMed ID: 31903916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
